Tiziana Reports Positive Phase 2a INFORM-MS Trial Results
Tiziana reported positive topline results from its Phase 2a INFORM-MS trial of intranasal foralumab in non-active secondary progressive multiple sclerosis.
Story updates
12:09:48 PM UTC
SquawkNews
Tiziana said its 12-week Phase 2a trial met its neuroinflammation endpoint for 50 μg intranasal foralumab versus placebo (p=0.0168) and safety objectives at both doses. Fatigue scores improved from baseline; the study was not powered to demonstrate definitive clinical changes.Material DetailsContex…